SEC filings
Idexx Laboratories (IDXX)
Recent filings Idexx Laboratories made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000874716All filings on SEC.gov
10-QQuarterly report
Quarterly report
Idexx Laboratories reported third-quarter 2026 revenue of $1.214 billion, up 9.9% year over year with 10.0% organic revenue growth, and income from operations of $402.3 million, up from $354.8 million a year earlier. …
8-KCurrent report
Results of Operations and Financial Condition
IDEXX Laboratories announced third-quarter 2026 financial results, with revenue of $1,214 million up 10% as reported and organic, EPS of $4.01 up 18% as reported, and raised full-year revenue and EPS guidance while lowering its reported…
10-QQuarterly report
Quarterly report
Idexx Laboratories' second-quarter 2026 revenue rose 9.7% to $1.22 billion and organic revenue growth was 9.0%, while income from operations climbed to $425.6 million from $373.0 million a year earlier. …
8-KCurrent report
Results of Operations and Financial Condition
IDEXX Laboratories reported second-quarter 2026 revenue of $1,217 million, up 10% as reported, and EPS of $4.27, up 18%, while raising its full-year 2026 revenue and EPS outlook. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Idexx Laboratories in Readster
Add Idexx Laboratories to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.